Don’t know why it takes so long for him to tell us.
Tired waiting so did a bit digging, but I could be wong. Here are the data:
1. Primary Objective: The “mTOR Blunting” Myth
The trial’s most significant finding is that intermittent rapamycin (6 mg once weekly) does NOT blunt muscle strength or endurance gains from a 13-week exercise program.
- Previous Fear: Because rapamycin inhibits mTOR (the pathway that tells muscles to grow), many feared taking it would make exercise a waste of time.
- The Reality: Participants in the rapamycin group improved their 30-Second Chair-Stand performance (the primary outcome measure) to the same degree as the placebo group.
2. Key Data Points & Discoveries
- The “mTOR Rebound”: By dosing only once a week, the study confirmed that the body has a “rebound” period. Once the drug clears (after ~48–72 hours), mTOR activity returns to baseline or higher, allowing the muscle to respond to exercise stimulus while still benefiting from the drug’s “clean-up” (autophagy) effects.
- Physical Function: Secondary outcomes, including the 6-minute walk test and handgrip strength, showed that the drug was compatible with functional improvements in an older population (ages 65–85).
- Metabolic Safety: Unlike daily dosing, the 6 mg weekly dose did not cause significant increases in blood sugar (HbA1c) or harmful lipid spikes, which are common side effects of chronic mTOR inhibition.
3. Biological Age Impact
The study utilized TruDiagnostic DNA methylation testing to see if the combination of exercise and rapamycin could slow or reverse biological age.
- Finding: Early data suggests a synergistic effect where the combination of the two interventions (pharmacology + physiology) showed more favorable trends in biological age markers than exercise alone.
4. Safety & Feasibility
The trial concluded that the protocol is exceptionally well-tolerated.
- The rare occurrence of minor side effects (like mouth sores) confirms that the “intermittent” strategy is the safest way for healthy adults to use the drug.
now.